Publications by authors named "Svetlana Stankovic"
Association of the Polymorphism rs3918242 of the Matrix Metalloproteinase-9 Gene with Coronary Artery Disease in a Younger Population.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
July 2023
Coronary artery disease (CAD) is a complex disease resulting from the interaction of numerous so-called traditional risk factors and comorbid conditions on the one side (such as dyslipidemia, smoking, obesity, diabetes, hypertension) and genetic factors on the other. The evidence of a genetic contribution to the development of CAD, especially in the last 2 decades is consistent. It is important that a number of established gene polymorphisms in the younger CAD population are in the genes involved in the inflammatory response and tissue maintenance and remodeling processes.
View Article and Find Full Text PDFDuration of Anticoagulation Therapy in Patients with Genetic Inherited Thrombophilia.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
July 2022
Genetic factors play an important role in deep vein thrombosis (DVT). The duration of anticoagulation therapy in patients with verified genetic inheritance and previous events of DVT is still questionable. We present three cases of siblings (two brothers and one sister) with verified Venous thromboembolism (VTE) and genetic inheritance.
View Article and Find Full Text PDFArticle Synopsis
- A multinational, noninterventional study was conducted to analyze the treatment patterns and disease progression in multiple myeloma (MM) patients starting new therapy between October 2010 and October 2012.
- A total of 2,358 patients were enrolled, with 775 undergoing stem cell transplantation (SCT) and 1,583 not, and their treatment histories along with other medical data were collected regularly.
- The study found varying response rates to treatment depending on whether patients underwent SCT and the types of therapies used, with overall response rates ranging from 49% to 97% across different treatment lines.
Introduction: VONCENTO® (CSL Behring) is a plasma-derived, high-concentration, low-volume, high-purity concentrate,which contains a high level of von Willebrand factor (VWF) high-molecular-weight multimers and aVWF/factor VIII (FVIII) ratio of ~2.4:1, similar to Haemate® P (CSL Behring).
Methods: The pharmacokinetic, efficacy and safety profiles of VONCENTO® were investigated in this multicentre,double-blind, randomised study.